image
Healthcare - Biotechnology - NASDAQ - US
$ 7.25
1.69 %
$ 277 M
Market Cap
-1.99
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one ITOS stock under the worst case scenario is HIDDEN Compared to the current market price of 7.25 USD, iTeos Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one ITOS stock under the base case scenario is HIDDEN Compared to the current market price of 7.25 USD, iTeos Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one ITOS stock under the best case scenario is HIDDEN Compared to the current market price of 7.25 USD, iTeos Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ITOS

image
$9.5$9.5$9.0$9.0$8.5$8.5$8.0$8.0$7.5$7.5$7.0$7.0$6.5$6.5$6.0$6.0$5.5$5.5$5.0$5.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
35 M REVENUE
177.89%
-160 M OPERATING INCOME
-5.58%
-134 M NET INCOME
-19.33%
-98.2 M OPERATING CASH FLOW
5.37%
-131 M INVESTING CASH FLOW
-180.50%
122 M FINANCING CASH FLOW
10883.02%
0 REVENUE
0.00%
-49.3 M OPERATING INCOME
-1.09%
-43.7 M NET INCOME
3.63%
5.5 M OPERATING CASH FLOW
114.72%
13.6 M INVESTING CASH FLOW
114.88%
285 K FINANCING CASH FLOW
164.48%
Balance Sheet iTeos Therapeutics, Inc.
image
Current Assets 510 M
Cash & Short-Term Investments 495 M
Receivables 5.91 M
Other Current Assets 8.98 M
Non-Current Assets 177 M
Long-Term Investments 160 M
PP&E 9.98 M
Other Non-Current Assets 7.1 M
72.00 %23.34 %Total Assets$687.0m
Current Liabilities 40.4 M
Accounts Payable 8.5 M
Short-Term Debt 1.34 M
Other Current Liabilities 30.5 M
Non-Current Liabilities 56.3 M
Long-Term Debt 3.76 M
Other Non-Current Liabilities 52.6 M
8.79 %31.57 %3.89 %54.37 %Total Liabilities$96.7m
EFFICIENCY
Earnings Waterfall iTeos Therapeutics, Inc.
image
Revenue 35 M
Cost Of Revenue 0
Gross Profit 35 M
Operating Expenses 195 M
Operating Income -160 M
Other Expenses -25.1 M
Net Income -134 M
40m40m20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)35m035m(195m)(160m)25m(134m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
-455.79% OPERATING MARGIN
-455.79%
-384.04% NET MARGIN
-384.04%
-22.77% ROE
-22.77%
-19.57% ROA
-19.57%
-27.50% ROIC
-27.50%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis iTeos Therapeutics, Inc.
image
600m600m500m500m400m400m300m300m200m200m100m100m00(100m)(100m)(200m)(200m)20192019202020202021202120222022202320232024202420252025
Net Income -134 M
Depreciation & Amortization 1.24 M
Capital Expenditures -1.63 M
Stock-Based Compensation 29.9 M
Change in Working Capital 18.6 M
Others 6.46 M
Free Cash Flow -99.8 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets iTeos Therapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for ITOS of $32.5 , with forecasts ranging from a low of $17 to a high of $46 .
ITOS Lowest Price Target Wall Street Target
17 USD 134.48%
ITOS Average Price Target Wall Street Target
32.5 USD 348.28%
ITOS Highest Price Target Wall Street Target
46 USD 534.48%
Price
Max Price Target
Min Price Target
Average Price Target
50504545404035353030252520201515101055Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 15
6. Ownership
Insider Ownership iTeos Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
38.6 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
5.71 K USD 1
9-12 MONTHS
7. News
iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025 WATERTOWN, Mass. and GOSSELIES, Belgium, March 25, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the poster presentations of preclinical data on EOS-215, a potential best-in-class antibody targeting TREM2, and a novel small molecule inhibiting PTPN1/2 at the American Association for Cancer Research (AACR) Annual Meeting, being held April 25-30, 2025 in Chicago, Illinois. globenewswire.com - 1 month ago
iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25 - Interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC with ~200 patients anticipated in 2025 - Completed enrollment of second dose cohort of EOS-984 + pembrolizumab combination in ongoing Phase 1 trial - EOS-215 Phase 1 trial TRM-010 patient enrollment anticipated to begin in 2Q25 - Cash balance and investment balance of $655.0 million as of December 31, 2024 expected to provide runway through 2027 globenewswire.com - 1 month ago
iTeos Therapeutics: Decimated By Collateral Events, Good Chances Of Success Nevertheless iTeos' lead molecule, Belrestotug, shows promising efficacy in trials despite setbacks in the anti-TIGIT space, with significant partnerships and a strong cash position. The stock has suffered due to failures of similar molecules from competitors, but iTeos' data remains positive, attracting major investments. Financially, iTeos has a solid runway with a market cap of $255mn and cash reserves nearly twice that, ensuring stability. seekingalpha.com - 2 months ago
All You Need to Know About iTeos Therapeutics (ITOS) Rating Upgrade to Buy iTeos Therapeutics (ITOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 3 months ago
iTeos Therapeutics: A Perhaps Unjustified Decline To End 2024 iTeos Therapeutics, Inc.'s lead candidate, belrestotug, shows promising response rates in lung cancer but faces challenges with increased toxicity and skepticism due to past failures in similar approaches. The company's financial health is strong, with over half a billion dollars in liquid assets and long-term investments, providing a substantial cushion for ongoing projects. Despite shelving inupadenant, the focus remains on belrestotug, with ongoing trials exploring its potential in various cancer indications. seekingalpha.com - 4 months ago
iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress - Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate (ORR) and a median PFS of 7.7 months for all evaluable patients across the cohorts - Recommended Phase 2 dose (RP2D) of inupadenant 80mg + carboplatin/pemetrexed demonstrated 73.3% ORR, with 64.6% of patients achieving landmark 6-month PFS - Inupadenant + carboplatin/pemetrexed safety profile was manageable and tolerable, with no dose-dependent toxicity observed - Inupadenant deprioritized to focus resources on other programs globenewswire.com - 4 months ago
iTeos to Participate in Upcoming Investor Conferences WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 26, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that company management will participate in two upcoming conferences in December: globenewswire.com - 5 months ago
iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates - EMA granted clearance to advance belrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in the EU - Interim data from inupadenant Phase 2 A2A-005 in 2L NSCLC at ESMO-IO - Completed enrollment of EOS-984 Phase 1 monotherapy dose escalation and initiated dosing of EOS-984 + pembrolizumab combination - Pro forma cash and investment balance of $683.9 million as of September 30, 2024 expected to provide runway through 2027 across a number of impactful portfolio milestones globenewswire.com - 5 months ago
Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths Biotech stocks Nuvalent and Iteos diverged Monday on updates for their lung cancer treatments at the ESMO meeting in Madrid. investors.com - 7 months ago
iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session U.S. stock futures were mixed this morning, with the Dow futures gaining around 100 points on Monday. benzinga.com - 7 months ago
iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGIT iTeos Therapeutics' belrestotug shows promising response rates in lung cancer trials, especially when combined with dostarlimab, despite significant safety concerns. Financially, ITOS has over 3 years of cash runway, bolstered by collaboration revenue, supporting its potential to reach critical milestones. The risks include small trial size, potential non-translation of response rates to survival benefits, and high-grade toxicities that could hinder approval. seekingalpha.com - 7 months ago
iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients - Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose - >30% cORR difference between belrestotug + dostarlimab vs dostarlimab monotherapy - Belrestotug + dostarlimab safety profile broadly consistent with known safety profile of checkpoint inhibitor combinations - GALAXIES Lung-301, global Phase 3 registration study, enrolling in same indication and setting - iTeos to host a conference call on Monday, September 16, 2024 at 8:00am ET globenewswire.com - 7 months ago
8. Profile Summary

iTeos Therapeutics, Inc. ITOS

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 277 M
Dividend Yield 0.00%
Description Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
Contact 321 Arsenal Street, Cambridge, MA, 02472-5710 https://www.iteostherapeutics.com
IPO Date July 24, 2020
Employees 173
Officers Mr. Philippe Brantegem Chief People Officer Dr. David Feltquate M.D., Ph.D. Chief Medical Officer Dr. Yvonne McGrath Ph.D. Chief Scientific Officer Mr. Matthew A. Call M.B.A. Chief Operating Officer Dr. Michel Detheux Ph.D. President, Chief Executive Officer & Director Ms. Adi Osovsky Executive Vice President of Legal Mr. Matthew Gall Chief Financial Officer